Parkinson's Disease Market Insights, Epidemiology and Forecasts, 2032 - Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Parkinson's Disease - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the Parkinson's disease, historical and forecasted epidemiology as well as the Parkinson's disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Parkinson's disease market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Parkinson's disease market size from 2019 to 2032. The report also covers current Parkinson's disease treatment practice/algorithm and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

The majority of Diagnosed Prevalent Parkinson's Disease patients were estimated in the US followed by EU4 and the UK, and Japan. The diagnosed patient of Parkinson's disease in the US were estimated to be approximately 1.2 million in 2022.

In 2022, the market size of Parkinson's disease was highest in the US among the 7MM accounting for approximately USD 1,820 million, and lowest in the United Kingdom with USD 135 million which is further expected to increase by 2032.

The total market size of the Parkinson's disease treatment market is anticipated to experience growth during the forecast period (2023-2032) due to emerging treatments that includes Tavapadon (Cerevel Therapeutics), P2B001 (Pharma Two B), ABBV-951 (AbbVie), BIIB122 (Biogen), Buntanetap (Annovis Bio), IPX203 (Amneal Pharmaceuticals), NE3107 (BioVie), CVN424 (Cerevance), ITI-214 (Intra-Cellular Therapies), and CNM-Au8 (Clene Nanomedicine), among others.

Gender-specific diagnosed prevalent cases of Parkinson's disease were higher in males (around 660 thousand cases) as compared to females (around 491 thousand) in 2022 in the US.

Parkinson's disease Treatment

The treatment landscape of Parkinson's disease consists of several medications, although none have yet reversed the effects of the disease. Levodopa is the gold standard for the treatment of motor symptoms. Further, it is common for people with Parkinson's disease to take a variety of these medications - all at different doses and at different times of day - to manage symptoms.

The medications used to treat Parkinson's disease include levodopa dopamine agonists MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2a antagonists. The main goal of these medications is to lessen motor symptoms or the symptoms that affect movement in people with Parkinson's disease.

There are multiple dopamine agonists available in the US including ropinirole (Requip, Requip XL), pramipexole (Mirapex, Mirapex ER), rotigotine (Neupro skin patch), and apomorphine (Apokyn subcutaneous injection).

Many molecules are in the pipeline to treat Parkinson's disease patients across the 7MM to cater to their needs. Some major products are anticipated hit the market during the study period 2019-2032, including tavapadon, P2B001, BIIB122, ABBV-951, and buntanetap.

Parkinson's disease Epidemiology

The total diagnosed prevalent cases of Parkinson's disease in the 7MM comprised of approximately 2.5 million cases in 2022 and are projected to increase during the forecasted period (2023-2032).

Parkinson's disease Drug Chapters

Drug chapter segment of the Parkinson's disease report encloses the detailed analysis of Parkinson's disease marketed drugs and late stage pipeline drugs. It also helps to understand the Parkinson's disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Emerging Drugs

Tavapadon: Cerevel Therapeutics/Pfizer

Cerevel Therapeutics is developing tavapadon to treat both early and late-stage Parkinson's disease. Tavapadon was rationally designed as an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes to balance meaningful motor activity with a favorable safety profile.

In July 2020, Cerevel Therapeutics and Arya Sciences Acquisition Corp II, a special purpose acquisition company or SPAC entered into a definitive business combination agreement. Upon closing of the transaction, Arya II will redomicile as a Delaware corporation, be renamed Cerevel Therapeutics Holdings, Inc., and its common stock was expected to be listed on Nasdaq under the ticker symbol "CERE" (the "Combined Company").

Parkinson's disease Market Outlook

For the purpose of study, the Parkinson's disease drugs market is categorized on the basis of medications treat Parkinson's disease including, levodopa dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2a antagonists.

GOCOVRI is the only medication approved by the US FDA for the treatment of dyskinesia - involuntary, jerky movements - in Parkinson's patients who receive levodopa-based therapy, with or without accompanying dopaminergic medications.

In the emerging scenario, several companies are creating medications to serve better treatment therapies for Parkinson's patients and are expected to enter the market including Tavapadon (Cerevel Therapeutics), P2B001 (Pharma Two B Ltd), BIIB122 (Biogen/ Denali Therapeutics), ABBV-951 (AbbVie), Buntanetap (Annovis Bio), IPX203 (Amneal Pharmaceuticals), RO7046015 (Hoffmann-La Roche), NE3107 (BioVie), CVN424 (Cerevance), CNM-Au8 (Clene Nanomedicine) and ITI-214 (Intra-Cellular Therapies, among others. They aim to investigate their products for the treatment of Parkinson's disease.

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Parkinson's disease Market Overview at a Glance

3.1. Market Share (%) Distribution of Parkinson's disease in 2019

3.2. Market Share (%) Distribution of Parkinson's disease in 2032

4. Executive Summary of Parkinson's disease

5. Key Events

6. Epidemiology and Market Methodology

7. Disease Background and Overview

7.1. Introduction

7.2. Classification

7.3. Signs and Symptoms

7.4. Risk Factors

7.5. Pathophysiology

7.6. Diagnosis

7.7. Treatment

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Total diagnosed Prevalent Population of Parkinson's disease

8.3. Assumptions and Rationale

8.4. The United States

8.5. EU4 and the UK

8.6. Japan

9. Patient Journey

10. Marketed Products

10.1. Key Cross Competition

10.2. XADAGO (safinamide): Newron Pharmaceuticals/Eisai/Meiji Seika Pharma

10.3. NOURIANZ (istradefylline): Kyowa Kirin

10.4. DUOPA (Carbidopa and Levodopa- ES): AbbVie

10.5. NUPLAZID (pimavanserin): Acadia Pharmaceuticals

10.6. INBRIJA (levodopa): Acorda Therapeutics

10.7. HARUROPI TAPE (ropinirole HCL transdermal patch): Hisamitsu Pharmaceutical/Kyowa Kirin

10.8. KYNMOBI (apomorphine HCI): Sunovion Pharmaceuticals

10.9. GOCOVRI (amantadine): Supernus Pharmaceuticals

10.10. ONGENTYS (opicapone): Neurocrine Biosciences/BIAL/Ono Pharmaceutical

10.11. OSMOLEX ER (amantadine): Supernus Pharmaceuticals

10.12. AZILECT (rasagiline): TevaPharmaceuticals/Lundbeck/Takeda

10.13. RYTARY (carbidopa and levodopa): Amneal Pharmaceuticals

11. Emerging Therapies

11.1. Key cross

11.2. Tavapadon: Cerevel Therapeutics/Pfizer

11.3. P2B001: Pharma Two B

11.4. ABBV-951 (foscarbidopa/ foslevodopa): AbbVie

11.5. BIIB122/ DNL151: Biogen/ Denali Therapeutics

11.6. Buntanetap: Annovis Bio

11.7. IPX203: Amneal Pharmaceuticals

11.8. NE3107: BioVie

11.9. CVN424: Cerevance

11.10. CNM-Au8: Clene Nanomedicine

11.11. ITI-214 (lenrispodun): Intra-Cellular Therapies

11.12. Prasinezumab (RO7046015/ RG7935/ PRX002): Hoffmann-La Roche/ Prothena Corporation

12. Parkinson's disease: The 7MM Analysis

12.1. Key Findings

12.2. Total Market Size of Parkinson's Disease in the 7MM

12.3. Market Outlook

12.4. Attribute Analysis

12.5. Key Market Forecast Assumptions

12.6. The United States Market Size

12.7. EU4 and the UK Market Size

12.8. Japan Market Size

13. KOL Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

16.1. The United States

16.2. EU4 and the UK

16.3. Japan

17. Acronyms and Abbreviations

18. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/wwbp5f

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900